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Sirtuin enzymes comprise a unique class of NAD+-
dependent protein deacetylases. Although struc-
tures of many sirtuin complexes have been deter-
mined, structural resolution of intermediate chemical
steps are needed to understand the deacetylation
mechanism. We report crystal structures of the
bacterial sirtuin, Sir2Tm, in complex with an S-alkyla-
midate intermediate, analogous to the naturally
occurring O-alkylamidate intermediate, and a Sir2Tm
ternary complex containing a dissociated NAD+ ana-
log and acetylated peptide. The structures and bio-
chemical studies reveal critical roles for the invariant
active site histidine in positioning the reaction inter-
mediate, and for a conserved phenylalanine residue
in shielding reaction intermediates from base ex-
changewith nicotinamide. The newstructural andbio-
chemical studies provide key mechanistic insight into
intermediate steps of the Sir2 deacetylation reaction.
INTRODUCTION
Sir2 enzymes comprise an ancient and well-conserved family of
NAD+-dependent deacetylases found in all domains of life (Frye,
2000). These remarkable enzymes, also known as sirtuins, use
NAD+ to catalyze the removal of acetyl groups from acetyl-lysine
residues on protein substrates, including histones (Imai et al.,
2000), Foxo transcription factors (Daitoku et al., 2004; Motta
et al., 2004), HIV TAT (Pagans et al., 2005), acetyl-CoA synthe-
tases (Starai et al., 2002), and p300 (Bouras et al., 2005). Numer-
ous biological processes, including aging (Kaeberlein et al.,
1999), HIV transcription (Pagans et al., 2005), gene silencing
(Johnson et al., 1990), chromatin structure (Fritze et al., 1997),
fat metabolism (Picard et al., 2004), and neurodegeneration
(Araki et al., 2004), are regulated by sirtuins.
The sirtuin enzymatic core is composed of a Rossmann fold
domain and a smaller domain comprising a helical bundle and
a zinc-binding motif (Avalos et al., 2002; Chang et al., 2002;
Finnin et al., 2001; Min et al., 2001; Zhao et al., 2003). NAD+
and the acetyl lysine bind in the active site cleft, which is located1368 Structure 16, 1368–1377, September 10, 2008 ª2008 Elseviebetween the two domains (Hoff et al., 2006). In the absence of
peptide, the nicotinamide and N-ribose of NAD+ can adopt
multiple conformations in the Sir2 active site (Avalos et al.,
2004; Zhao et al., 2003). Upon binding acetyl-lysine, NAD+
adopts a strained conformation that buries the nicotinamide
ring deep within the active site (Hoff et al., 2006). In this state,
the acetyl-lysine is oriented to react with NAD+. The strained
NAD+ conformation, which was trapped in the crystal structure
of a Michaelis complex, suggests that Sir2 enzymes destabilize
NAD+. Subsequent intermediate steps of the Sir2 deacetylation
reaction, including the formation of the peptidyl-imidate interme-
diate, have not been structurally characterized.
In the deacetylation reaction, Sir2 enzymes consume onemol-
ecule of NAD+ and an acetylated lysine substrate, generating the
deacetylated lysine, nicotinamide, and themetabolite, 20-O-ace-
tyl-ADP-ribose (Jackson et al., 2003; Sauve et al., 2001). In the
first step of the Sir2 deacetylation reaction, the glycosidic
bond between nicotinamide and the N-ribose is broken, and
ADP-ribose is transferred to the acetyl amide oxygen to generate
a peptidyl-imidate species, also termed the O-alkylamidate
intermediate (Sauve et al., 2001; Smith and Denu, 2006;
Figure 1A). The reaction mechanism for sirtuins could follow
that of other ADP ribosyl-N-ribosyltransferases. These reactions
are characterized by loss of the nicotinamide group prior to the
addition of the nucleophile from the alpha-face of the ribosyl
group. The reactive riboxacarbenium is then activated to react
with unreactive nucleophiles, like the carbonyl oxygen of ace-
tyl-lysine. These mechanisms involve migration of the anomeric
carbon of the ribosyl group to accomplish nucleophilic displace-
ment by electrophile migration, while the position of the leaving
group and the attacking nucleophile remain stationary (Schramm
and Shi, 2001). This mechanism is analogous to that used by the
NAD+ hydrolase/ADP-ribosyl cyclase, CD38, and other N-ribo-
syltransferases (Sauve et al., 1998; Sauve and Schramm,
2004). An alternative mechanism has been suggested where
the initial step proceeds through an SN2 nucleophilic attack of
the acetyl amide oxygen on NAD+ with involvement of the amide
oxygen, suggesting a transition state with significant SN2
character (Smith and Denu, 2007b).
Following formation by Sir2 of the O-alkylamidate intermedi-
ate, a catalytic histidine activates the 20 OH group of the
N-ribose, which then attacks the intermediate, forming a 1’,2’
bicyclic species and the deacetylated lysine (Sauve et al.,r Ltd All rights reserved
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Structural Studies of Sir2 Reaction Intermediates2006). Subsequent hydrolysis of the bicyclic species yields the 20
O-acetyl ADP ribose product (Jackson and Denu, 2002; Sauve
et al., 2001; Figure 1A). The Sir2 deacetylation reaction is po-
tently inhibited through a base-exchange reaction with the reac-
tion product, nicotinamide. In this process, nicotinamide attacks
the peptidyl-imidate intermediate to regenerate NAD+ and
reform acetylated lysine (Jackson et al., 2003; Sauve and
Schramm, 2003). Nicotinamide analogs, such as isonicotina-
mide, that are chemically inert in the exchange reaction activate
sirtuins in vivo and in vitro by preventing nicotinamide rebinding
(Howitz et al., 2003; Sauve et al., 2005). Other sirtuin activators
function by different mechanisms (Howitz et al., 2003). To fully
understand sirtuin deacetylation activity, a structure-based
elucidation of the Sir2 deacetylation reaction is desirable.
Sir2 enzymes must overcome several challenges to success-
fully deacetylate a substrate. These include transferring ADP-
ribose to an amide oxygen, protecting the peptidyl-imidate inter-
mediate from hydrolysis (Smith and Denu, 2006), deprotonating
the N-ribose 20 OH to form the bicyclic species (Figure 1A), and
protecting the peptidyl-imidate intermediate from base
exchange with nicotinamide (Jackson et al., 2003; Sauve and
Schramm, 2003). Hydrolysis of the O-alkylamidate intermediate
to ADP-ribose is observed for a HST2 H135A mutant enzyme,
demonstrating that theO-alkylamidate intermediate is susceptible
to hydrolysis (Smith and Denu, 2006). It is unclear how Sir2 en-
zymes shield the peptidyl-imidate intermediate from these off-
pathway reactions. The final challenge for Sir2 enzymes is to use
Figure 1. Sirtuin Deacetylation Reaction
Mechanism
(A and B) (A) In the first step of the Sir2 deacetyla-
tion reaction (I), the ADP-ribose moiety of NAD+ is
transferred to acetyl-lysine, generating the O-alky-
lamidate intermediate. In this step (I), the nicotin-
amide-N-ribose bond is broken to generate free
nicotinamide. Next, the N-ribose 20OH group at-
tacks the O-alkylamidate intermediate, generating
a 10,20 bicyclic species (II). Subsequent hydrolysis
of the 10,20 bicyclic species yields deacetylated ly-
sine and 20O-acetyl-ADP-ribose (III). The structure
of the DADMe-NAD+ analog, which represents
a dissociated NAD+ species, is depicted in (B).
the N-ribose 20 secondary alcohol to
attack the peptidyl-imidate and form the
1’,2’ bicyclic intermediate (Figure 1A), as
typical secondary alcohols require activa-
tion to become good nucleophiles. It has
been proposed that a conserved active-
site histidine activates the 20 OH directly
or through a shuttling mechanism with
the 30 OH, but mutation of this conserved
histidine to alanine resulted in only a mod-
est decrease in deacetylation activity of
the Thermotoga maritima Sir2 enzyme,
and a tenfold decrease in kcat for HST2
(Hoff et al., 2006; Smith and Denu, 2006).
Structural information on reaction interme-
diates is needed to provide insight into the
formation of the bicyclic species, nicotinamide inhibition, and
other intermediate steps of the Sir2 deacetylation reaction.
To resolve key questions regarding the intermediate steps
in the Sir2 deacetylation reaction, we have determined the
structure of a bacterial sirtuin, Sir2Tm, bound to a trapped S-al-
kylamidate intermediate, which is amimic of the natural peptidyl-
imidate complex. This structure is the first direct visualization of
a Sir2-ribosylated peptide intermediate complex and, in combi-
nation with biochemical data, helps to dissect key intermediate
steps in the Sir2 deacetylation reaction. To explore the N-ribose
nicotinamide glycosidic bond cleavage, we solved the structure
of a Sir2-acetyl peptide-DADMe-NAD+ (an analog of a dissoci-
ated NAD+) ternary complex. The structures and biochemical
data presented here help expand ourmechanistic understanding
of Sir2-mediated deacetylation and serve as a foundation to
begin to understand other Sir2 enzymatic activities.
RESULTS
Structure of a Sir2-Acetylated Peptide–DADMe-NAD+
Analog Ternary Complex
The transfer of ADP-ribose from NAD+ to the acetyl-lysine and
removal of the nicotinamide moiety is a poorly understood step
of the Sir2 deacetylation reaction. This glycosidic bond cleavage
andADP ribosyl transfer reaction could proceed through a disso-
ciative mechanism that has SN1 characteristics (Hoff et al.,
2006). Because NAD+ can adopt numerous conformations in
Structure 16, 1368–1377, September 10, 2008 ª2008 Elsevier Ltd All rights reserved 1369
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Structural Studies of Sir2 Reaction Intermediatesthe Sir2 active site (Avalos et al., 2004; Zhao et al., 2003), we
determined how an analog of nicotinamide-dissociated NAD,
DADMe-NAD+ (Figure 1B), binds to the Sir2 active site.
DADMe-NAD+ is an analog of an elongated NAD+ designed to
mimic dissociative transition states. In the ADP-ribosylating
toxins from organisms causing cholera, pertussis, and diptheria,
the inhibition gave Km/Ki ratios of 200, 0.48, and 0.3 respec-
tively (Zhou et al., 2004). With Km and Ki values of 125 and
360 uM, respectively, the interaction of DADMe-NAD+ with this
sirtuin is similar to that for pertussis and diptheria toxins (see
Figure S1 available online). To explore the nature of this transfer
step, we solved the structure of Sir2Tm bound together with
acetylated peptide and the NAD+ analog, DADMe-NAD+
(Figure 1B and Figure 2). The DADMe-NAD+ compound mimics
dissociation of nicotinamide from ADP ribose by placing a meth-
ylene group between the N-ribose and nicotinamide moiety. The
nitrogen in the nicotinamide ring is replaced by a carbon, giving
the ring a neutral charge that would be expected followingmigra-
tion of the positive charge onto the ribosyl group. The C10 carbon
of the N-ribose is replaced by a nitrogen to mimic the cationic
character of an oxacarbenium-like species. The pKa of this nitro-
gen is 8.4, providing a mixture of neutral and cationic forms
under the crystallization conditions (Zhou et al., 2004).
The overall structure of the Sir2Tm-acetylated peptide–
DADMe-NAD+complex is similar to that of theMichaelis complex
of the same sirtuin (Hoff et al., 2006; Figure 2B). There is little re-
arrangement of the Sir2Tm active site. The electron density for
the DADMe-NAD+ molecule and acetylated lysine residue is
well defined and allows for the positioning of these moieties
(Figure 2A). The DADMe-NAD+ analog binds in the substrate
binding cleft in a similar conformation to that of NAD+ in the Mi-
chaelis complex, differing from the NAD+ conformation in other
Sir2-NAD+ complexes (Avalos et al., 2004; Zhao et al., 2003)
(Figure 2B). The DAD ribose N10, analogous to the C10 of the
NAD+ N-ribose, is positioned proximal to the acetylated lysine
amide oxygen (Figure 2). The DADMe-NAD+ benzamide ring
bound to the C pocket superimposes with the nicotinamide ring
in the Sir2 Michaelis complex and is bound by identical Sir2 pro-
tein side chains and water contacts (Figure 2B). The ribose of
DADMe-NAD+ adopts a similar orientation to the Michaelis com-
plex N-ribose, except that it is closer to the acetyl amide oxygen
(Figure 2B). Themigration of N10 fromDADMe-NAD+ to a position
closer to the acetyl amide oxygen while the nicotinamide analog
remains in the same position is expected from a dissociative
mechanism, where the ribosyl ribocation migrates from the nico-
tinamide, gains chemical reactivity at the transition state, and
completes the reaction coordinate by migrating to react with
the fixed carbonyl oxygen. DADMe-NAD+ is larger than NAD+
by the insertion of themethylene bridge (Figure 1). In a SN2mech-
anism, this increased atomic size in theNAD+ reaction coordinate
would be expected to induce a steric clash to the acetyl-lysine,
causing some displacement of the acetyl group. Instead, the
structure shows alignment consistent with distances in the cata-
lytic site for a mechanism of ribosyl migration.
An S-alkylamidate Reaction Intermediate Is Trapped
in Sir2Tm Crystals
After the glycosidic bond linking nicotinamide to the N-ribose of
NAD+ is cleaved, ADP-ribose is transferred to the acetyl-lysine,1370 Structure 16, 1368–1377, September 10, 2008 ª2008 Elsevieforming a proposed O-alkylamidate intermediate (Sauve et al.,
2001). Although this intermediate has not been directly ob-
served, kinetic experiments (Smith and Denu, 2006) and isotope
labeling (Sauve et al., 2001) support its existence. Another study
used a thioacetyl peptide to trap a species in the Sir2 deacetyla-
tion reaction, and used mass spectrometry to identify a trapped
species with amolecular weight corresponding to an S-alkylami-
date or 10,20 bicyclic species (Smith and Denu, 2007a). An
average carbon-sulfur bond is 1.8 A˚, whereas a typical carbon-
oxygen bond is around 1.4 A˚. In the S-alkylamidate compound,
the observed carbon-sulfur bond distance is 1.79 A˚. The elon-
gated carbon-sulfur bond length in the S-alkylamidate could
result in reduced turnover, as previously proposed (Smith and
Denu, 2007a). Sir2Tm-acetyl peptide cocrystals are catalytically
active when soaked with NAD+, but product turnover is not
observed for hours (Hoff et al., 2006). The slow kinetics of the
Sir2Tm crystals coupled with the reported 80-fold decrease in
turnover rate for the thioacetyl peptide suggested that it should
be possible to trap an S-alkylamidate intermediate in Sir2Tm
crystals (Hoff et al., 2006; Smith and Denu, 2007a). To provide
direct evidence for the existence of the O-alkylamidate interme-
diate, as well as mechanistic insights into the intermediate
chemical steps of the Sir2 deacetylation reaction, we trapped
an S-alkylamidate intermediate in the crystal and determined
its structure at 2.5 A˚ resolution (Figure 3).
Figure 2. Structure of a Sir2Tm-Acetylated Peptide–DADMe-NAD+
Analog Ternary Complex
(A) The 2Fo-Fc (1s) electron density map showing the position of the acetyl
group and DADMe-NAD+ analog.
(B) Superposition of the Sir2-acetyl peptide DADMe-NAD+ structure (blue) with
the Sir2 Michaelis complex (yellow; PDB ID code 2H4H).r Ltd All rights reserved
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Structural Studies of Sir2 Reaction IntermediatesA comparison of the Sir2-Michaelis and Sir2-S-alkylamidate
complex structures indicates that only small movements are
necessary to convert NAD+ and acetyl lysine into the O-alkylami-
date intermediate in the Sir2 deacetylation reaction (Figure 4).
The phosphate groups undergo little movement, and are in sim-
ilar positions in both the Sir2-Michaelis and Sir2-S-alkylamidate
intermediate complexes. The acetyl lysine amide oxygen moves
0.8 A˚, accounting for a rotation of the acetyl group by 30,
whereas the N-ribose plane tilts 35, resulting in the N-ribose
20OH group moving 1.8 A˚. The small displacements of the N-ri-
bose and acetyl groups between the Sir2 Michaelis and S-alky-
lamidate complexes orients the 20OH group 2.6 A˚ from the acetyl
group in the S-alkylamidate structure (Figure 3D). In this confor-
mation, the S-alkylamidate 20OH is oriented to form the 10,20
bicyclic species, which is the next proposed intermediate in
the Sir2 deacetylation reaction (Figure 1A). As predicted, the rel-
ative stability of the S-alkylamidate intermediate could be the
result of inefficient attack of the 20OH on the S-alkylamidate
due to the increased C-S bond distance of 1.79 A˚ (Smith and
Denu, 2007a).
The observed S-alkylamidate conformation in the Sir2-S-alky-
lamidate complex structure is stabilized by an extended hydro-
gen bond network consisting of backbone and side chain
contacts (Figure 3C). Key conserved side chains in this network
Figure 3. Structure of a Sir2Tm-S-Alkylami-
date Intermediate Complex
(A) The Fo-Fc omit electron density map (2.5 s)
showing the S-alkylamidate intermediate.
(B) The 2Fo-Fcmap (1s) showing the same view as
in (A).
(C) Hydrogen bond network between side chains
in Sir2Tm (grey) and the S-alkylamidate intermedi-
ate (pink).
(D) Distances measured in angstroms between
atoms of the S-alkylamidate and Sir2Tm H116.
include His116, Gln98, and Asn99, which
aid in positioning the N- ribose moiety of
the intermediate in a conformation that
is poised to form the bicyclic intermedi-
ate. The conserved active site histidine,
His116, is 2.5 A˚ from the ribose 20OH and
3.5 A˚ from the 30OH group (Figure 3D).
By comparison, this histidine is 3.3 A˚ from
both the 20OH and 30OH groups in the
unreacted Michaelis complex structure
(Hoff et al., 2006). We previously sug-
gested that His116 could deprotonate
the 20 OH group through a shuttling
mechanism where H116 deprotonates
the 30OH, which in turn deprotonates the
20 OH, thus promoting its reactivity to-
ward forming the 10,20 bicyclic species
(Hoff et al., 2006). However, the Sir2Tm
S-alkylamidate complex structure dem-
onstrates that if H116 is indeed a general
base, it can directly deprotonate the N-ri-
bose 20 OH because His116 is in contact
with the N-ribose 20 OH (Figure 3D). Based on the Sir2
deacetylation reaction mechanism, the O-alkylamidate interme-
diate 3-nitrogenwould carry a positive charge, which is stabilized
by a hydrogen bond to the backbone carbonyl of Val160
(Figure 3C).
The O-alkylamidate is a sufficiently long-lived intermediate
that Sir2 enzymes must shield it from hydrolysis long enough
to permit base exchange with nicotinamide. Failure to prevent
hydrolysis would yield an ADP ribose hydrolysis product, as
observed for the HST2 H135A mutant enzyme (Smith and
Denu, 2006). The base exchange reaction—which regenerates
the starting reactants acetyl lysine and NAD+ and is exploited
by the cell to regulate sirtuin activity (Sauve and Schramm,
2003)— must be controlled so that the deacetylation reaction
is not largely aborted. The O-alkylamidate intermediate is sus-
ceptible to methanolysis, which yields b-10-O-methyl ADP-ri-
bose (Smith and Denu, 2006). Aborting the Sir2 deacetylation re-
action could be biologically important in cases where
deacetylation is not needed by the cell (Sauve and Schramm,
2003). To protect the O-alkylamidate intermediate from these re-
actions, the Sir2 active site contains a cluster of conserved phe-
nylalanines that shield the intermediate from attack by water.
These residues, including Phe33, Phe48, and Phe162, stack
against the S-alkylamidate intermediate, physically shielding it
Structure 16, 1368–1377, September 10, 2008 ª2008 Elsevier Ltd All rights reserved 1371
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Structural Studies of Sir2 Reaction Intermediatesfrom solvent (Figure 5A). Phe48 and Phe162 in the Sir2Tm-S-al-
kylamidate structure stack against the acetyl lysine. In this con-
formation, Phe48 and Phe162 are also positioned to protect the
O-alkylamidate intermediate. In the Michaelis complex, Phe33
stacks against the nicotinamide moiety (Figure 5B). This Phe33
conformation would not, however, protect the O-alkylamidate
intermediate from base exchange or solvent hydrolysis. Instead,
Phe33 moves following cleavage of the nicotinamide-ribose gly-
cosidic bond to stack against the O-alkylamidate intermediate in
an orientation that blocks base exchange with nicotinamide
(Figures 5B and 5C). The conformation of Phe33 in the Sir2 S-al-
kylamidate structure is similar to that observed in the structure of
Sir2Tm bound to the products O-acetyl-ADP ribose and nicotin-
amide (Avalos et al., 2005; Figure 5C). In this state, the conforma-
tion of Phe 33 in the S-alkylamidate intermediate complex
structure would sterically clash with the nicotinamide moiety in
both the Sir2 products and Michaelis complex structures, sug-
gesting that Phe 33 may be involved in expelling nicotinamide
from the Sir2 active site as previously suggested (Avalos et al.,
2005). In the presence of excess nicotinamide, a robust nicotin-
amide exchange reaction occurs, making the reverse reaction
that reforms enzyme-bound N-acetyl peptide and NAD+
more probable than formation of 20-O-Ac-ADPR, nicotinamide,
and deacetylated peptide (Jackson et al., 2003; Sauve and
Schramm, 2003). There is no electron density corresponding to
nicotinamide in the Sir2-S-alkylamidate electron density maps.
Based on previous structures of Sir2 bound to nicotinamide,
free nicotinamide binds in a cleft called the C pocket (Avalos
et al., 2005). In the S-alkylamidate structure, the dimensions of
this C pocket are constricted and would not accommodate
nicotinamide, suggesting that nicotinamide was expelled from
this site.
To verify the proposed role of Phe33 in protecting the O-alky-
lamidate intermediate from hydrolysis and the base exchange
reaction with nicotinamide, which regenerates acetyl-lysine and
NAD+, we produced Sir2Tm F33A mutant protein and compared
its enzymatic properties with wild-type Sir2Tm. The other phe-
nylalanine residues, F162 and F48, are located in positions crit-
ical for acetyl-lysine binding or structural integrity of Sir2Tm, so
these residues were not mutated. A standard NAD+ consump-
tion assay, in which the NAD+ concentration was fixed at 1 mM
and acetyl peptide was varied, revealed that the kcat for NAD
+
consumption of the Sir2Tm F33A mutant enzyme, 0.3 s1, is sig-
nificantly lower than that of the wild-type protein, 5.9 s1
(Figure 6A). To determine if the Sir2Tm F33A protein is more
susceptible to nicotinamide inhibition, assays were performed
with [14C]nicotinamide at various nicotinamide concentrations
(Figure 6B), and the reaction products were run on silica TLC
plates to separate unconsumed nicotinamide and NAD+. As
can be seen in Figure 6B, there is significantly more base ex-
change with the Sir2F33A mutant, implicating Phe33 in prevent-
ing base exchange (Figure 6B). Consistent with this observation,
Figure 4. Comparison of the Sir2Tm-Michaelis and Sir2Tm-S-Alkyla-
midate Complexes
Superposition of the acetyl-lysine and a portion of the NAD+ in the Sir2Tm-
Michaelis structure (blue) with the-S-alkylamidate intermediate (gray).
Figure 5. A Conserved Cluster of Phenylalanines Protects the Pep-
tidyl-Imidate Intermediate from Hydrolysis and Base Exchange
with Nicotinamide
(A) Cluster of phenylalanine side chains (red), Phe33, Phe48, and Phe162, that
shield the S-alkylamidate intermediate from solvent. (B) Orientation of Phe33
side chain in the Michaelis complex (blue) and in the structure containing the
S-alkylamidate intermediate (grey). (C) Conformation of Phe 33 in the
Sir2Tm-S-alkylamidate intermediate (pink) as compared with its position in
the structure of Sir2Tm bound to the deacetylation reaction product, nicotina-
mid (green; PDB ID code 2H4J).
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inhibition, with an IC50 value for the Sir2Tm F33A enzyme of
0.1 mM, which is at least three orders of magnitude lower than
that of the wild-type enzyme, 480 mM (Figure 6C). Sir2Tm wild-
type and Sir2TmF33A reactions were analyzed by reverse-phase
high-performance liquid chromatography (HPLC) (Figure 7). The
major nucleotide product observed for the wild-type enzyme is
O-acetyl-ADP-ribose; the F33A mutant enzyme reactions con-
tained NAD+ and ADP-ribose. These results are consistent with
the role of F33A in shielding the O-alkylamidate intermediate
from solvent hydrolysis and base exchange with nicotinamide.
DISCUSSION
The Sir2Tm structures and biochemical studies presented here,
taken together with previous work, provide important new
insights into the intermediate steps in the Sir2 deacetylation
mechanism. A previous study describing the wild-type Michaelis
complex containing Sir2Tm bound to both acetylated peptide
Figure 6. Enzymatic Characterization of the Sir2Tm F33A Enzyme
(A) The rate of NAD+ consumption as a function of acetylated peptide concen-
tration for wild-type (red) and the F33A mutant Sir2Tm (red). Error bars repre-
sent the standard deviation between the duplicates. The kcat of the mutant
enzyme is 0.3 sec1, versus 5.9 sec1 for the wild-type enzyme.
(B) Base exchange assays using [14C]nicotinamide were performed on wild-
type Sir2Tm and on the F33Amutant, and the products separated by thin-layer
chromatography on a silica plate.
(C) Nicotinamide inhibition assays showing percent change in deacetylation
activity as a function of nicotinamide concentration. Data for the wild-type
enzyme are indicated with open circles and a blue curve; data for the F33A
mutant are indicated with filled circles and a red line. The IC50 for the mutant
enzyme is 0.1 mM, and that of the wild-type enzyme is 480 mM.
Figure 7. HPLC Analysis of Sir2Tm Reactions
The Sir2Tm (green) and Sir2Tm F33A reactions (red) were analyzed by reverse-
phase HPLC. Standards were run to identify reaction components (blue).
Structure 16, 1368–1377, September 10, 2008 ª2008 Elsevier Ltd All rights reserved 1373
Structure
Structural Studies of Sir2 Reaction Intermediatesand NAD+ (Hoff et al., 2006) revealed that the acetyl oxygen of
acetyl-lysine was poised to attack the C10 of NAD+. In the
Michaelis complex, the acetyl-lysine inserts into the active site
through a hydrophobic tunnel proximal to the N-ribose of
NAD+, which promotes binding of the nicotinamide moiety of
NAD+ in the hydrophobic C pocket. It was proposed (Hoff
et al., 2006) that the observed configuration of cosubstrates pro-
moted cleavage of the first step in the deacetylation reaction,
namely the cleavage of the glycosidic bond to release nicotin-
amide, in two ways: by burying the charged nicotinamide ring
in the hydrophobic C pocket, and by rotating the carboxamide
out of plane. In addition to these destabilizing interactions, the
adjacent N-ribose is relatively flattened, as compared with the
more highly puckered sugar seen in NAD+ that is not constrained
to insert into the C pocket (Avalos et al., 2004). The net effect
would be to promote the dissociation of nicotinamide and forma-
tion of a transition state with oxacarbenium-like character, which
could then be attacked by the acetyl oxygen.
The structure of a Sir2Tm ternary complex containing an acet-
ylated peptide and a mimic of a nicotinamide-dissociated NAD+
species DADMe-NAD+ (Figure 2) shows how the active site
accommodates this dissociated NAD+ species. The DADMe-
NAD+ molecule mimics a dissociated NAD+ species, where
positive charge develops on the N-ribose ring, and the nicotin-
amide-N-ribose bond is elongated (Figure 1B). As expected for
a dissociative-like transition state, the Sir2Tm-DADMe-NAD+-
acetyl peptide shows that the acetyl-lysine and nicotinamide re-
main fixed relative to their Michaelis complex positions, whereas
the reactive riboxacarbenium migrates toward and is trapped by
the acetyl-lysine, forming the O-alkylamidate intermediate.
The Sir2Tm–S-alkylamidate structure gives the first structural
evidence for the existence of the unusual O-alkylamidate chem-
ical species and provides mechanistic insight into the intermedi-
ate steps in the Sir2 reaction (Figure 3). The active site histidine,
His116 in Sir2Tm, has been proposed to act as a general base by
abstracting a proton from the N-ribose 20OH to form the bicyclic
intermediate (Hoff et al., 2006; Smith and Denu, 2006). Kinetic
studies of Sir2 enzymes, including Sir2Tm and HST2, demon-
strate that mutating the catalytic histidine, His116, to alanine
modestly reduces the enzymatic activity (Smith and Denu,
2006). The Sir2-S-alkylamidate structure reveals why this
histidine residue is dispensable for Sir2 deacetylation. In the
S-alkylamidate structure, His116 positions the N-ribose of the in-
termediate (Figure 3C). In addition to His116, other Sir2 side
chain and backbone atoms contact the S-alkylamidate interme-
diate, including the universally conserved residue Gln98
(Figure 3C). Mutating His116 to alanine would result in the loss
of two hydrogen bonds to the N-ribose, but because there are
four other hydrogen bonds, this deletion would not be expected
to significantly alter the conformation of the S-alkylamidate inter-
mediate. This suggests that mutation of H116 to alanine only
slightly lowers Sir2 activity because other Sir2 backbone and
side chain hydrogen bonds are in place to position the pep-
tidyl-imidate intermediate for subsequent chemical steps (Fig-
ures 3C and 3D). Subsequent formation of the bicylic species
could then occur (Figure 3D). Once the O-alkylamidate interme-
diate adopts the proper conformation, the reactivity of this
species could then drive the formation of the 10,20 bicyclic
intermediate.1374 Structure 16, 1368–1377, September 10, 2008 ª2008 ElsevieSir2 enzymes must protect the peptidyl-imidate intermediate
from hydrolysis, which would abort the deacetylation reaction.
Failure to shield the peptidyl-imidate intermediate would
produce ADP ribose hydrolysis products and not the proper
product, 20-O-acetyl-ADP-ribose (Smith and Denu, 2006). Two
atoms in the peptidyl-imidate intermediate that are sensitive to
hydrolysis are the C10 of the N-ribose moiety and the carbon
from the acetyl group (Figure 5A). Our structure reveals that, al-
though a small portion of the intermediate is exposed to solvent,
including the ribose ring oxygen, S-alkylamidate sulfur, and
methyl group from the acetyl moiety, no atoms susceptible to
hydrolysis are solvent exposed (Figure 5A). Conserved aromatic
residues including Phe33, Phe48, and Phe162 protect the O-al-
kylamidate intermediate from hydrolysis. ADP-ribose is a reac-
tion product of the Sir2F33A enzyme (Figure 7), demonstrating
that this conserved residue protects the O-alkylamidate from
solvent hydrolysis.
Sir2 enzymes permit the O-alkylamidate intermediate to react
with nicotinamide in a base exchange reaction, but this interme-
diate must also be converted to the 10,20-bicyclic intermediate to
complete deacetylation (Figure 1A). When nicotinamide reacts
with the O-alkylamidate intermediate, it becomes a potent inhib-
itor of sirtuins in vitro and in vivo (Bitterman et al., 2002). Yeast
treated with nicotinamide show a decreased level of transcrip-
tional silencing, similar to that observedwhen Sir2 is deleted (Bit-
terman et al., 2002). It was previously demonstrated that free
nicotinamide binds in a region called the C pocket, which is
also where the nicotinamide moiety of NAD+ binds (Avalos
et al., 2005). Free nicotinamide bound in the C pocket can then
undergo base exchange with the O-alkylamidate intermediate
to regenerate NAD+ (Avalos et al., 2004, 2005; Hoff et al.,
2006). To prevent base exchange, Phe33 stacks against the
ribose moiety of the S-alkylamidate intermediate, physically
blocking the C10 from attack by nicotinamide (Figure 5C). Muta-
tion of this conserved phenylalanine in yeast dramatically lowers
Sir2-mediated gene silencing and in vivo activity (Armstrong
et al., 2002).
Previous structural studies indicated that Phe33 could adopt
multiple conformations and serve as a gatekeeper that regulates
base exchange (Avalos et al., 2005). The active site from the Sir2
Michaelis complex (Hoff et al., 2006) and the Sir2 S-alkylamidate
complex described here are highly similar except for the confor-
mation of Phe33 and the diameter of the nicotinamide exit tunnel
(Figure 5B). The conformation of Phe33 in the Sir2-S-alkylami-
date is consistent with our earlier proposal that this side chain
could stabilize an oxacarbenium intermediate through pi-cation
interactions (Hoff et al., 2006). Phe33 adopts a conformation in
the Sir2-S-alkylamidate structure that constricts the putative nic-
otinamide exit tunnel observed in previous Sir2Tm structures
(Figure 5). This conserved phenylalanine adopts multiple confor-
mations in different structures and, in the Michaelis conforma-
tion, would allow for diffusion of nicotinamide out of the active
site upon formation of the O-alkylamidate intermediate
(Figure 5B). The conformation of Phe33 in the S-alkylamidate
complex would clash with the nicotinamide moiety of NAD+ in
the Sir2 Michaelis complex conformation, suggesting Sir2 en-
zymes could use Phe33 to expel nicotinamide from the active
site through an exit tunnel (Figures 5B and 5C). As an added
safeguard, the conformation of Phe33 further constricts ther Ltd All rights reserved
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reentry into the active site for as long as the Phe33 side chain re-
mains in the observed position. The importance of Phe33 is
further highlighted by comparing the enzymatic properties of
Sir2TmF33Awith thewild-type enzyme. Sir2TmF33A is three or-
ders of magnitude more sensitive to nicotinamide inhibition, has
a lower kcat for NAD
+ consumption, and a greater amount of nic-
otinamide base exchange activity (Figure 6). Further, the Sir2Tm
F33A mutant protein had ADP-ribose as a reaction product,
which was not observed for the Sir2Tm wild-type enzyme
(Figure 7). These biochemical results, in conjunction with the
Sir2Tm-S-alkylamidate intermediate structure, emphasize that
Phe33 is a gatekeeper for regulating Sir2-mediated base
exchange and solvent hydrolysis. This residue is found in virtually
all sirtuins, pointing to the importance of this residue in regulating
Sir2 chemistry. The structures and biochemical data presented
here reveal insight into intermediate steps of the Sir2 deacetyla-
tion and help motivate future studies to further characterize Sir2
reaction intermediates.
EXPERIMENTAL PROCEDURES
Protein Expression, Purification, and Crystallization
Thermotogamaritima Sir2 enzymes were expressed and purified as previously
described (Smith et al., 2002). The mutagenesis of Sir2Tm was carried out by
using QuickChange (Stratagene). A dissociative NAD+ analog, DADMe-NAD+,
was designed to contain a neutral analog of nicotinamide and a cationic mimic
of the ribocationic group for a dissociated nicotinamide-ribosyl bond. Synthe-
sis also included a methylene bridge to provide stability in the pyrophosphate
bridge linking the AMP and NMN analog groups (Zhou et al., 2004). Geometry
appropriate to a dissociated NAD+ state was provided by a methylene group
linking the nicotinamide and ribosyl cation mimics (Figure 1).
To produce crystals of the Sir2Tm DADMe NAD+-acetyl peptide complex,
Sir2Tm at 16 mg/ml wasmixed with 5 ml of 40 mM p53 acetylated p53 peptide,
KKGQSTSRHK(Kac)LMFKTEG, to give a final solution containing 10 mg/ml
Sir2Tm and 4 mM acetyl peptide. Crystals of the Sir2Tm-acetyl p53 peptide
were grown in 100 mM CHES (pH 9.5) and 15% PEG 3350 by vapor diffusion.
The crystals formed in the space group P212121 with unit cell dimensions
a = 45.8 A˚, b = 59.7 A˚, and c = 106 A˚. Crystals were then soaked for 13 hr in
cryoprotectant with 5 mM DADMe-NAD+, 100 mM CHES [pH 9.5], 20% PEG
3350).
To produce crystals of the Sir2-S-alkylamidate intermediate complex, 25 ml
of Sir2Tm (20 mg/ml) was incubated 1 hr on ice with 5 ml of an N-3-thioacetyl-
lysine peptide (22 mM) derived from the p53 sequence, KKGQSTSRHK(Ks-ac)
LMFKTEG (Fatkins et al., 2006). Onemicroliter of Sir2-thiopeptide solution was
then mixed with 1 ml of a crystallization solution consisting of 13%–15%
PEG3350 (w/v) and 0.1 M CHES (pH 9.5). The hanging-drop vapor-diffusion
method was used to grow crystals of the Sir2-thiopeptide complex. After
2 days, crystals appeared of the Sir2-peptide complex. The crystals formed
in the space group P212121 with unit cell dimensions a = 46.5 A˚, b = 60.4 A˚,
and c = 107 A˚. Crystals were allowed to grow for an additional week, and
then soaked for 0.5–13 hr in a cryoprotective solution containing 20%
PEG3350, 0.1 M ChES (pH 9.5), and 0.5 mM NAD+. Soaks with higher NAD+
concentrations resulted in significant crystal cracking. After soaking, crystals
were flash frozen in liquid nitrogen.
Sir2-DADMe-NAD+-Acetyl P53 Peptide Complex Crystallographic
Data Collection and Processing
X-ray diffraction data were recorded from frozen Sir2-DADMe-NAD+-acetyl
p53 peptide crystals at beamline GM/CA-CAT24D at the Argonne National
Laboratory equipped with a quantum CCD detector. Data were reduced with
HKL2000 (Otwinowski and Minor, 1997) and CCP4 (1994). Initial phases
were calculated using Sir2Tm bound to p53 acetyl peptide (PDB ID code
2H4F). Model building was done with Coot (Emsley and Cowtan, 2004), andStructure 16, 1368–1refinement was performed with CNS (Bru¨nger et al., 1998) and CCP4 (1994).
Crystallographic statistics are summarized in Table 1.
Sir2-S-Alkylamidate Complex Crystallographic Data Collection
and Processing
Diffraction data were recorded from frozen Sir2-thiopeptide crystals at the
BioCARS facility at Argonne National Laboratory on the 14-BM-C beamline
equipped with an ADSC Quantum-315 detector. Data were processed and re-
duced with HKL2000 (Otwinowski and Minor, 1997) and CCP4 (1994). The
structure was solved by molecular replacement with MOLREP implemented
in CCP4 using the apo structure of Sir2Tm (PDB ID code 2H4F) as the search
model. The initial molecular replacement solution was subjected to rigid body
refinement, followed by conjugate gradient and simulated annealing refine-
ment in CNS (Bru¨nger et al., 1998).
The structure of Sir2Tm bound to a reactive intermediate was solved bymo-
lecular replacement using the Sir2 apoenzyme as the searchmodel, and differ-
ence maps were inspected to determine if the S-alkylamidate intermediate
was present. The intermediate was fit to the electron density and included in
the remaining stages of refinement. Removal of the S-alkylamidate intermedi-
ate and refinement of the Sir2-peptide complex increase R and Rfree by 1.5
percentage points. Because the sulfur is electron rich, its position was con-
firmed by contouring the simulated annealing omit Fo-Fc map at 5s. To inves-
tigate whether other intermediates were present in the crystal, the proposed
1’,2’ bicyclic intermediate (Figure 1), substrates, and Sir2 reaction products
were also modeled but did not fit the electron density. With the occupancy
set at 1, the average B factor for the S-alkylamidate intermediate is 77 A˚2.
Because the B factor and occupancy are coupled parameters, an elevated
B factor could suggest a lower occupancy for the S-alkylamidate intermediate.
Reducing the occupancy of the intermediate to 0.7 gave an average B factor
Table 1. Crystallographic Statistics
Crystal Thio Intermediate DAD TS Structure
Diffraction data
Space group P212121 P212121
Unit cell (A˚) 46.5, 60.4, 107 45.8, 59.7, 106
Resolution 2.5 A˚ 1.9 A˚
Measured reflections 40,888 60,754
Unique reflections 10,834 22,339
Completeness (%) 99.5 (96.0) 99.6 (96.4)
Avg I/Sigma 14.3 15.2
Multiplicity 2.1 3.2
Rmerge 0.11 (.45) 0.10 (.37)
Refinement
Resolution range (A˚) 23.9–2.5 50–1.9
Reflections 10,834 22,339
Working 10,287 21,169
Test (5%) 547 1170




Water molecules 87 145
R (%) 22.4 19.7
Rfree (%) 24.5 22.9
rmsd
Bond lengths (A˚) 0.015 .016
Bond angles () 1.6 1.4
Numbers in parentheses indicate statistics for the outermost shell.377, September 10, 2008 ª2008 Elsevier Ltd All rights reserved 1375
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Structural Studies of Sir2 Reaction Intermediatesfor the intermediate of 33 A˚2 with similar R and Rfree values and virtually iden-
tical electron density. Because the intermediate was obtained by soaking crys-
tals, it is likely that some of the Sir2 complexes in the crystal do not contain the
S-alkylamidate intermediate, resulting in a lower occupancy for the S-alklami-
date intermediate.
The S-alkylamidate intermediate and flexible loop regions were built into
difference electron density maps using Coot (Emsley and Cowtan, 2004).
There was clear density defining the S-alkylamidate covalent linkage, N-ribose
moiety, and phosphate groups. The density defining the adenine ring was am-
biguous in the Fo-Fc omit maps, but improves in the 2Fo-Fc electron density
maps of the solved structure. Crystallographic statistics are summarized in
Table 1. Figures were generated with PyMOL (Delano Scientific; San Carlos,
CA).
Enzymatic Assays
NAD+ consumption assays were preformed with the same reaction conditions
as described previously (Avalos et al., 2004). Briefly, 50 mg/ml of Sir2Tm wild-
type or Sir2Tm F33A protein were incubated at 37C for 15 min with 1 mM of
NAD+, but the NAD+ concentration was quantified using a fluorescence-based
assay described in Putt and Hergenrother, (2004) for Sir2Tm and Sir2Tm F33A.
Data were fit with the Michaelis-Menton equation in SigmaPlot. Nicotinamide
base exchange and inhibition reactions were preformed as described (Avalos
et al., 2005). Fifty micrograms per milliliter of Sir2Tm wild-type or Sir2Tm F33A
protein were incubated at 37C for 15 min with 125 mM of NAD+, 500 mm of
acetyl p53 peptide, and various concentrations of [14C]nicotinamide. Base
exchange reactions were resolved on a silica TLC plate with an 80:20 ratio of
ethanol/ammonium acetate buffer. Nicotinamide inhibition reactions were per-
formed with 50 mg/ml of Sir2Tm wild-type or Sir2Tm F33A protein incubated
at 37C for 15min with 125 uM of NAD+, 500 mMof acetyl p53 peptide, and var-
ious concentrations of nicotinamide. Nicotinamide inhibition data were fit with
the following equation to determine the IC50 value for nicotinamide in SigmaPlot:
VI =Voð1 ½I=ðIC50 + IÞÞ;
where Vo is the initial rate of uninhibited reaction and vI is the initial rate of
reaction in the presence of inhibitor.
HPLC Analysis of Sir2 Reactions
Sir2Tm enzyme, 50 mg/ml, was incubated with 125 mM NAD+ and 125 mM
acetyl p53 peptide at 37C for various times (5 min to 6 hr). Reactions were re-
solved by reverse phase HPLC on aWaters Nova-PAK C18 3.93 150 mm col-
umn. Buffer A was 0.05% TFA and buffer B was 0.05% TFA in acetonitrile.
A 0%–40% gradient of buffer B was run with a flow rate of 1 ml/min.
ACCESSION NUMBERS
The coordinates for the Sir2Tm-p53 peptide-DADMe-NAD+ and Sir2Tm-S-al-
kylamidate structures have been deposited in the Protein Data Bank under ID
codes 3D4B and 3D81.
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